Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ELITE PHARMACEUTICALS INC /NV/

ELTP · OTC · CIK 0001053369 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

42.1 / 100

1 buyers · 1 purchase transaction lines · $8.7K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+1.4 / 25
Role+20.0 / 20
Recency+3.7 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Dash Barry HDirector
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Dash Barry H · $8.7K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-19–2026-08-19

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

42.1 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 42.4
  2. 42.4
  3. 42.3
  4. 42.2
  5. 42.1

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
0Sales
1Other Form 4 lines
2SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+4.0%
3M
-29.7%
6M
-31.6%
12M
-58.7%

Volatility & liquidity

Volatility
73.1%
Beta
—
Avg daily value
USD 204,863

Valuation

Market cap
USD 280.1M
P/E
6.2×

Fundamentals

Profit margin
30.1%
ROE
45.4%
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin, ROE · Fiscal year ended: 2026-03-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-06-27 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
2,632,127
Previous report
2,606,630
Avg daily volume
1,177,443
Days to cover
2.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-19Dash Barry HPurchase (P)Common Stock30,000USD 0.29USD 8,700SEC filing ↗
2025-07-10Kirkov KirkoPurchase (P)Common Stock16,366USD 0.59USD 9,656SEC filing ↗

Form 4 evidence

2 transaction lines in the latest 365-day window; 27 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-19Dash Barry HPurchase (P)Common Stock30,000USD 0.29USD 8,700SEC filing ↗
2026-01-09Plassche DouglasOption exercise / conversion (M)Stock Options (right to buy)2,500,000USD 0.03USD 75,000SEC filing ↗
Show recent Form 4 evidence (2 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-19Dash Barry HPurchase (P)Common Stock30,000USD 0.29USD 8,700SEC filing ↗
2026-01-09Plassche DouglasOption exercise / conversion (M)Stock Options (right to buy)2,500,000USD 0.03USD 75,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerELTP
CIK0001053369
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeOTC

Data coverage

Local Form 4 history27 transaction lines from 2020-06-30 to 2026-08-19
2 P purchase lines · 5 S sale lines · 20 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.